Company / Operating Margin
BioNexus Gene Lab Corp Operating Margin History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-39.9%
FY2025
5-year range
-39.9% / 7.9%
FY2021-FY2025
Trend
-141.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin has fluctuated over the past 7 years, ranging from -217.2% in FY2019 to 11.2% in FY2020.
Based on SEC 10-K filings.
-39.9% in FY2025 with a 5-year CAGR of -51.1%.
Declined from -26.5% to -39.9% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -37.3pp
- 5-Year Change
- -51.1pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, operating margin decreased 141.3% year-over-year.
- Peak operating margin was recorded in FY2020.
- Lowest operating margin in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -39.9% | -141.3% |
| FY2024 | -16.6% | +37.6% |
| FY2023 | -26.5% | -897.7% |
| FY2022 | -2.7% | -133.7% |
| FY2021 | 7.9% | -29.3% |
| FY2020 | 11.2% | +105.1% |
| FY2019 | -217.2% | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026